Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets

Free Radical Biology and Medicine

Volumn 45, Issue 4, 2008, Pages 512-520

  Schildknecht, Stefan ^a   van der Loo, Bernd ^b   Weber, Klaus ^c   Tiefenthaler, Katja ^c   Daiber, Andreas ^d   Bachschmid, Markus Michael ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Herz Zentrum Bodensee   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Nitric oxide; Peroxide tone; Peroxynitrite; Platelets; Prostaglandin endoperoxide synthase; Superoxide; Thromboxane A2

Indexed keywords

CALCIMYCIN; NITRIC OXIDE; PEROXIDE; PEROXYNITRITE; PROSTAGLANDIN SYNTHASE; SUPEROXIDE; THROMBOXANE A2;

ADULT; ARTICLE; CHEMICAL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS;

CYCLOOXYGENASE 1; HUMANS; PEROXYNITROUS ACID; PLATELET AGGREGATION; THROMBOXANE A2;

EID: 46649087526     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.04.042     Document Type: Article

References (61)

1. Vericel E., Croset M., Sedivy P., Courpron P., Dechavanne M., and Lagarde M. Platelets and aging. Aggregation, arachidonate metabolism and antioxidant status. Thromb. Res. 49 3 (1988) 331-342
2. Vericel E., Januel C., Carreras M., Moulin P., and Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 53 4 (2004) 1046-1051
3. Salvemini D., de Nucci G., and Vane J.R. Superoxide dismutase cooperates with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma. Thromb Haemost. 65 4 (1991) 421-424
4. Charo I.F., Feinman R.D., Detwiler T.C., Smith J.B., Ingerman C.M., Silver, and M. J. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion. Nature 269 5623 (1977) 66-69
5. Hamberg M., Svensson J., and Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U. S. A. 72 8 (1975) 2994-2998
6. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
7. Calzada C., Vericel E., and Lagarde M. Low concentrations of lipid hydroperoxides prime human platelet aggregation specifically via cyclo-oxygenase activation. Biochem. J. 325 Pt 2 (1997) 495-500
8. Schildknecht S., Bachschmid M., and Ullrich V. Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells. FASEB J. 19 9 (2005) 1169-1171
9. Fujimoto Y., Uno E., and Sakuma S. Effects of reactive oxygen and nitrogen species on cyclooxygenase-1 and-2 activities. Prostaglandins, Leukot. Essent. Fatty. Acids 71 5 (2004) 335-340
10. Dietz R., Nastainczyk W., and Ruf H.H. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur. J. Biochem. 171 1-2 (1988) 321-328
11. Karthein R., Dietz R., Nastainczyk W., and Ruf H.H. Higher oxidation states of prostaglandin H synthase. EPR study of a transient tyrosyl radical in the enzyme during the peroxidase reaction. Eur. J. Biochem. 171 1-2 (1988) 313-320
12. Smith W.L., and Lands W.E. Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochemistry 11 17 (1972) 3276-3285
13. Kulmacz R.J., and Wang L.H. Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J. Biol. Chem. 270 41 (1995) 24019-24023
14. Schildknecht S., Bachschmid M., Baumann A., and Ullrich V. COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. FASEB J. 18 6 (2004) 757-759
15. Frein D., Schildknecht S., Bachschmid M., and Ullrich V. Redox regulation: a new challenge for pharmacology. Biochem. Pharmacol. 70 6 (2005) 811-823
16. Bachschmid M., Schildknecht S., and Ullrich V. Redox regulation of vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem. Biophys. Res. Commun. 338 1 (2005) 536-542
17. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271 5 Pt 1 (1996) C1424-1437
18. Clavreul N., Adachi T., Pimental D.R., Ido Y., Schoneich C., Cohen, and R. A. S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. FASEB J. 20 3 (2006) 518-520
19. Yamakura F., Taka H., Fujimura T., and Murayama K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem. 273 23 (1998) 14085-14089
20. Zou M.H., and Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 382 1-2 (1996) 101-104
21. Sase K., and Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 57 22 (1995) 2049-2055
22. Seno T., Inoue N., Gao D., Okuda M., Sumi Y., Matsui K., Yamada S., Hirata K.I., Kawashima S., Tawa R., Imajoh-Ohmi S., Sakurai H., and Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res. 103 5 (2001) 399-409
23. Krotz F., Sohn H.Y., Gloe T., Zahler S., Riexinger T., Schiele T.M., Becker B.F., Theisen K., Klauss V., and Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100 3 (2002) 917-924
24. Chlopicki S., Olszanecki R., Janiszewski M., Laurindo F.R., Panz T., and Miedzobrodzki J. Functional role of NADPH oxidase in activation of platelets. Antioxid. Redox Signal. 6 4 (2004) 691-698
25. Ambrosio G., Golino P., Pascucci I., Rosolowsky M., Campbell W.B., DeClerck F., Tritto I., and Chiariello M. Modulation of platelet function by reactive oxygen metabolites. Am. J. Physiol. 267 1 Pt 2 (1994) H308-H318
26. Boulos C., Jiang H., and Balazy M. Diffusion of peroxynitrite into the human platelet inhibits cyclooxygenase via nitration of tyrosine residues. J. Pharmacol. Exp. Ther. 293 1 (2000) 222-229
27. Hecker G., Utz J., Kupferschmidt R.J., and Ullrich V. Low levels of hydrogen peroxide enhance platelet aggregation by cyclooxygenase activation. Eicosanoids 4 2 (1991) 107-113
28. Lufrano M., and Balazy M. Interactions of peroxynitrite and other nitrating substances with human platelets: the role of glutathione and peroxynitrite permeability. Biochem. Pharmacol. 65 4 (2003) 515-523
29. Moro M.A., Darley-Usmar V.M., Goodwin D.A., Read N.G., Zamora-Pino R., Feelisch M., Radomski M.W., and Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc. Natl. Acad. Sci. U. S .A. 91 14 (1994) 6702-6706
30. Nowak P., and Wachowicz B. Peroxynitrite-mediated modification of fibrinogen affects platelet aggregation and adhesion. Platelets 13 5-6 (2002) 293-299
31. Sabetkar M., Low S.Y., Naseem K.M., and Bruckdorfer K.R. The nitration of proteins in platelets: significance in platelet function. Free Radic. Biol. Med. 33 6 (2002) 728-736
32. Spiecker M., Darius H., and Meyer J. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo. Thromb Res. 70 5 (1993) 405-415
33. Yin K., Lai P.S., Rodriguez A., Spur B.W., and Wong P.Y. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets. Prostaglandins 50 3 (1995) 169-178
34. Beharka A.A., Wu D., Serafini M., and Meydani S.N. Mechanism of vitamin E inhibition of cyclooxygenase activity in macrophages from old mice: role of peroxynitrite. Free Radic. Biol. Med. 32 6 (2002) 503-511
35. Freedman J.E., Parker III C., Li L., Perlman J.A., Frei B., Ivanov V., Deak L.R., Iafrati M.D., and Folts J.D. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 103 23 (2001) 2792-2798
36. Freedman J.E., Li L., Sauter R., and Keaney J.J. alpha-Tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release. FASEB J. 14 15 (2000) 2377-2379
37. Pignatelli P., Di Santo S., Buchetti B., Sanguigni V., Brunelli A., and Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J. 20 8 (2006) 1082-1089
38. Kuzkaya N., Weissmann N., Harrison D.G., and Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem. Pharmacol. 70 3 (2005) 343-354
39. van der Donk W.A., Tsai A.L., and Kulmacz R.J. The cyclooxygenase reaction mechanism. Biochemistry 41 52 (2002) 15451-15458
40. Landino L.M., Crews B.C., Timmons M.D., Morrow J.D., and Marnett L.J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 93 26 (1996) 15069-15074
41. Siess W. Molecular mechanisms of platelet activation. Physiol. Rev. 69 1 (1989) 58-178
42. Yu Y., Cheng Y., Fan J., Chen X.S., Klein-Szanto A., Fitzgerald G.A., and Funk C.D. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J. Clin. Invest 115 4 (2005) 986-995
43. Upmacis R.K., Deeb R.S., and Hajjar D.P. Regulation of prostaglandin H2 synthase activity by nitrogen oxides. Biochemistry 38 38 (1999) 12505-12513
44. Low S.Y., Sabetkar M., Bruckdorfer K.R., and Naseem K.M. The role of protein nitration in the inhibition of platelet activation by peroxynitrite. FEBS Lett. 511 1-3 (2002) 59-64
45. Arnold W.P., Mittal C.K., Katsuki S., and Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. U. S. A. 74 8 (1977) 3203-3207
46. Radomski M.W., Palmer R.M., and Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br. J. Pharmacol. 101 2 (1990) 325-328
47. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., and Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 100 2 (1997) 350-356
48. Moro M.A., Darley-Usmar V.M., Lizasoain I., Su Y., Knowles R.G., Radomski M.W., and Moncada S. The formation of nitric oxide donors from peroxynitrite. Br. J. Pharmacol. 116 3 (1995) 1999-2004
49. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., Radomski M.W., and Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 93 4 (1996) 1480-1485
50. Schrammel A., Pfeiffer S., Schmidt K., Koesling D., and Mayer B. Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol. Pharmacol. 54 1 (1998) 207-212
51. Negrescu E.V., Grunberg B., Kratzer M.A., Lorenz R., and Siess W. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc. Drugs Ther. 9 4 (1995) 619-629
52. Gerzer R., Karrenbrock B., Siess W., and Heim J.M. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. Thromb. Res. 52 1 (1988) 11-21
53. Fisch A., Michael-Hepp J., Meyer J., and Darius H. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. Eur. J. Pharmacol. 289 3 (1995) 455-461
54. Jourd'heuil D., Jourd'heuil F.L., Kutchukian P.S., Musah R.A., Wink D.A., and Grisham M.B. Reaction of superoxide and nitric oxide with peroxynitrite. Implications for peroxynitrite-mediated oxidation reactions in vivo. J. Biol. Chem. 276 31 (2001) 28799-28805
55. Goodwin D.C., Gunther M.R., Hsi L.C., Crews B.C., Eling T.E., Mason R.P., and Marnett L.J. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J. Biol. Chem. 273 15 (1998) 8903-8909
56. Gunther M.R., Hsi L.C., Curtis J.F., Gierse J.K., Marnett L.J., Eling T.E., and Mason R.P. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J. Biol. Chem. 272 27 (1997) 17086-17090
57. Tsai A.L., Wei C., and Kulmacz R.J. Interaction between nitric oxide and prostaglandin H synthase. Arch. Biochem. Biophys. 313 2 (1994) 367-372
58. Adachi T., Weisbrod R.M., Pimentel D.R., Ying J., Sharov V.S., Schoneich C., and Cohen R.A. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat. Med. 10 11 (2004) 1200-1207
59. Schildknecht S., Daiber A., Ghisla S., Cohen R.A., and Bachschmid M.M. Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite. FASEB J. 22 1 (2008) 215-224
60. Violi F., Pratico D., Ghiselli A., Alessandri C., Iuliano L., Cordova C., and Balsano F. Inhibition of cyclooxygenase-independent platelet aggregation by low vitamin E concentration. Atherosclerosis 82 3 (1990) 247-252
61. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., and FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96 1 (1999) 272-277